GYRE THERAPEUTICS INC (GYRE)
US4037831033 - Common Stock
| MRQ (2024-9-30) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 15.87M | 33.51M | 21.70M | 44.30M | 30.40M | |||
| Marketable Securities | 9.23M | N/A | 0.00 | 2.50M | 49.00M | |||
| Receivables | 20.77M | 16.84M | 5.00M | 1.80M | 3.30M | |||
| Inventories | 6.38M | 4.28M | N/A | N/A | N/A | |||
| Other Current Assets | 2.56M | 2.59M | 1.50M | 2.80M | 6.80M | |||
| Total Current Assets | 54.81M | 57.22M | 28.20M | 51.50M | 89.50M | |||
| Non-Current Assets | ||||||||
| PPE Net | 26.43M | 23.78M | 100.00K | 3.70M | 2.30M | |||
| Investments And Advances | 29.52M | 23.43M | N/A | 0.00 | 2.50M | |||
| Intangibles | 184.00K | 205.00K | N/A | N/A | N/A | |||
| Other Non-Current Assets | 9.41M | 7.18M | 200.00K | 500.00K | 500.00K | |||
| Total Non-Current Assets | 70.43M | 59.32M | 200.00K | 4.20M | 5.30M | |||
| TOTAL ASSETS | 125.24M | 116.54M | 28.40M | 55.70M | 94.80M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Accrued Expenses | 10.25M | 12.14M | 4.10M | 7.50M | 9.90M | |||
| Accounts Payable | 303.00K | 355.00K | 200.00K | 6.40M | 5.90M | |||
| Other Current Liabilities | 4.17M | 7.55M | 12.60M | 200.00K | 2.00M | |||
| Total Current Liabilities | 14.72M | 20.05M | 16.80M | 14.20M | 17.80M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Other Non-Current Liabilities | 12.05M | 18.02M | 0.00 | 400.00K | 1.00M | |||
| Total Non-Current Liabilities | 47.34M | 47.80M | 0.00 | 400.00K | 1.00M | |||
| TOTAL LIABILITIES | 62.06M | 67.84M | 16.80M | 14.60M | 18.80M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -70.26M | -82.44M | -410.90M | -402.70M | -314.80M | |||
| Additional Paid In Capital | 134.30M | 68.18M | 389.20M | 443.80M | 390.80M | |||
| Minority Interest | 35.30M | 29.78M | N/A | N/A | N/A | |||
| Common Shares | 85.00K | 64.60M | 33.30M | 0.00 | 0.00 | |||
| Other Shareholders' Equity | -946.00K | -1.64M | N/A | 0.00 | 0.00 | |||
| Shares Outstanding | 85.77M | 76.60M | 2.50M | 2.10M | 1.50M | |||
| Tangible Book Value per Share | 0.73 | -0.21 | -8.68 | 19.57 | 50.73 | |||
| Total Shareholders' Equity | 63.18M | 48.70M | 11.60M | 41.10M | 76.10M | |||
| TOTAL LIABILITIES AND EQUITY | 125.24M | 116.54M | 28.40M | 55.70M | 94.80M | |||
| Statistics | ||||||||
| Current Ratio | 3.72 | 2.85 | 1.68 | 3.63 | 5.03 | |||
| Return On Assets (ROA) | -61.45% | -79.74% | -29.01% | -157.86% | -59.32% | |||
| Return On Equity (ROE) | -121.81% | -190.84% | -71.03% | -213.94% | -73.90% | |||
| Return On Invested Capital (ROIC) | 31.09% | 15.73% | N/A | N/A | N/A | |||
| Return On Invested Capital Ex Cash (ROICexc) | 40.23% | 24.10% | N/A | N/A | N/A | |||
| Return On Invested Capital Ex Cash + Goodwill (ROICexcg) | 40.31% | 24.18% | N/A | N/A | N/A | |||
All data in USD , ROIC based on taxRate of 0.21